Integumen wins Labskin contracts with two cosmetics giants
Integumen on Friday signed agreements with a combined value of more than £100,000 to test products and ingredients from two top 10 global cosmetics companies.
FTSE AIM All-Share
These customers have previously purchased the company's Labskin products but have now requested a full virtual service offering, with the potential for continued testing thereafter.
The AIM-traded company said its LabskinAI platform has now completed beta testing and has fully transitioned to a virtual and physical test platform for healthcare, personal care, skincare, wound care and pharmaceutical drug discovery.
Gerard Brandon, chief executive of Integumen, said: "Integumen is playing a major role in the creation of an innovative AI eco-system that will contribute to the growth of our clients' product range as they develop new skin care products using the LabskinAI virtual platform. Right now, LabskinAI serves as a portal for small, medium and large corporations to meet the strict EU regulatory requirements for existing products that are already on the shelf."
Integumen's shares were up 0.70% at 1.96p at 1041 BST.